KPTI - Karyopharm Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

273.4M

Cash

148.6M

Avg Qtr Burn

-29.38M

Short % of Float

17.43%

Insider Ownership

9.64%

Institutional Own.

62.57%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma, Diffuse large B cell lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib Details Myelofibrosis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) + pomalidomide + dexamethasone Details Multiple myeloma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Endometrial cancer, Cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) Details Myelofibrosis, Primary immune thrombocytopenia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) + mezigdomide Details Multiple myeloma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eltanexor Details Myelodysplastic syndrome, Blood cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Glioblastoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Rare diseases, Liposarcoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KPT-9274 (PAK4 and NAMPT inhibitor) Details Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) + rituximab-gemcitabine-dexamethasone-platinum (R-GDP) Details Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.